EVAX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Evaxion Biotech AS · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.82 USD
-4.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -23.7% below the Trend Line and sits at 3.1% of its 52-week range. The latest completed week returned -4.7%, after a -17.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 17 out of 100
Latest Close 2.82 USD 31 Jul 2026
1W Return -4.7% latest completed week
4W Return -17.3% short-term follow-through
12W Return -35.0% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.7% Latest completed week; four-week move -17.3%. Indicator stack 25/26 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 41.25% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 44 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -23.7% below the Trend Line and sits at 3.1% of its 52-week range. The latest completed week returned -4.7%, after a -17.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.15

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -17.3% over four weeks, -35.0% over 12 weeks, and 8.0% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.7%
4W-17.3%
12W-35.0%
26W-11.3%
52W8.0%
Active trend streak0 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.04Latest activity-pressure read.
Pressure change-69.9%Four-week change in activity pressure.
Leadership-37.68Latest relative-leadership reading.
RS change-36.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value55/100Relative valuation strength. Underlying universe rank 46; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-48.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.7%
Gross profit retained from each unit of revenue.
Operating margin
-184.7%
Operating profit retained from revenue.
Free-cash-flow margin
-87.9%
Free cash flow generated from revenue.
Return on invested capital
-460.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
121.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-93.8%
Net share repurchases relative to market value.
Shareholder yield
-93.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 44 relevant articles.

5 positive · 34 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-76.8%Distance below the 52-week high.
13-week volatility6.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+32.3%Week of 13 Mar.
Worst week-16.2%Week of 19 Jun.
Latest week-4.7%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses7
Sharp losses8
Recent vol6.7%13-week weekly-return volatility.
Base vol12.5%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew10.7% / -8.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 41.25%

Next-week expectancy is negative with a 41.25% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 44 relevant articles.

Evaxion Biotech A/S (EVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.82 USD-4.7%3.69 USD12.92 USD-1.04-37.6870.2KOff
24 Jul 20262.96 USD-3.7%3.76 USD13.28 USD-0.92-34.3444.4KOff
17 Jul 20263.08 USD-3.0%3.83 USD13.67 USD-0.87-32.9892.7KOff
10 Jul 20263.17 USD-7.0%3.88 USD14.05 USD-0.83-33.8474.3KOff
3 Jul 20263.41 USD10.4%3.98 USD14.43 USD-0.61-27.63100.2KOff
26 Jun 20263.09 USD1.3%4.05 USD14.83 USD-0.44-33.77113.6KOff
19 Jun 20263.05 USD-16.2%4.14 USD15.23 USD-0.13-37.59136.1KOff
12 Jun 20263.64 USD2.5%4.21 USD15.60 USD0.18-23.59148.9KOff
5 Jun 20263.55 USD-11.3%4.27 USD16.00 USD0.32-23.81214.4KOff
29 May 20264.00 USD-2.0%4.37 USD16.39 USD0.45-18.23132.5KOff
22 May 20264.08 USD4.1%4.42 USD16.84 USD0.49-14.02103.9KOff
15 May 20263.92 USD-9.7%4.49 USD17.31 USD0.46-15.90179.9KOff
8 May 20264.34 USD-3.4%4.58 USD17.84 USD0.43-6.60134.8KOff
1 May 20264.50 USD11.5%4.63 USD18.32 USD0.272.98125.4KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.